公司概述
Lantern Pharma Inc. is a biotechnology enterprise dedicated to the discovery and development of oncology drugs, with a primary operational focus on the Indian market. As a participant in the healthcare sector, specifically within the biotechnology industry, the company aims to advance novel therapeutic combinations for serious conditions such as non-small cell lung cancer adenocarcinoma. The firm operates on a modest scale, boasting a market capitalization of $21.05M, a workforce of 16 employees, and no reported annual revenue. This limited revenue figure, combined with a market cap of $21.05M, indicates that the company is in an early-stage development phase where valuation is driven primarily by the potential of its clinical pipeline rather than current commercial sales. The small employee count of 16 further contextualizes the organization as a lean, asset-light entity typical of pre-revenue biotech firms that are heavily reliant on successful clinical trial outcomes to achieve commercial viability.
财务健康
The company reports N/A for revenue and N/A for annual revenue, while its Net Income over the trailing twelve months stands at $-17,119,438 and EBITDA is recorded at $-17,961,214. The absence of positive revenue alongside a significant net loss reveals a cost structure dominated by research and development expenditures rather than commercial operating costs, as the firm has not yet generated substantial sales to offset these outlays. Free cash flow for the period is $-9,179,892, which indicates a high consumption of cash reserves required to fund ongoing clinical trials and operational expenses without external capital infusion. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, reflecting the fact that the company has not yet generated revenue to calculate meaningful profitability percentages. In terms of liquidity, the company holds $10.12M in cash against a total debt burden of $78,539, resulting in a Debt to Equity ratio of 1.20. Despite the low absolute debt level, the debt-to-equity ratio of 1.20 suggests a leveraged capital structure relative to the small equity base, though the massive cash pile provides a substantial buffer against short-term obligations. The Current Ratio is 2.40, indicating that the company possesses 2.40 dollars of current assets for every dollar of current liabilities, which points to a healthy short-term liquidity position capable of meeting immediate financial commitments. Return on Equity is -123.5% and Return on Assets is -61.4%, metrics that reveal that management is currently deploying capital to generate losses rather than profits, a common characteristic of biotechnology firms in the clinical development stage where capital efficiency is measured by pipeline advancement rather than shareholder returns.
估值评估
The Trailing Twelve Months P/E Ratio is N/A, while the Forward P/E is listed as -0.93, implying that earnings are expected to remain negative or that the market is pricing in significant uncertainty regarding future profitability trajectories. The Price to Book ratio stands at 3.22, suggesting that the market values the company at more than three times its net asset value, a premium often attributed to the intangible value of the clinical-stage drug pipeline which is not fully captured on the balance sheet. Alternative valuation metrics such as Price to Sales are N/A due to the lack of revenue, and the EV/EBITDA is -0.61, which further underscores the speculative nature of the valuation where traditional earnings-based multiples are not applicable. The stock has traded between a 52-Week High of $5.74 and a 52-Week Low of $1.11, with the current market price fluctuating within this established range. The Beta value is 1.75, indicating that the stock's price volatility is significantly higher than the broader market, moving approximately 75% more aggressively than the market index in response to price swings. These valuation dynamics highlight the high risk profile associated with investing in a pre-commercial biotechnology company where the primary asset is the intellectual property and clinical progress of its oncology drug candidates.
Growth & Income
Revenue Growth and Earnings Growth are both reported as N/A, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated from commercial data. Consequently, earnings are not growing in the traditional sense, as the company is currently burning cash to advance its pipeline rather than scaling revenue streams. Regarding income, the company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning all available financial resources are being reinvested directly into research, development, and clinical trial costs rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology firms in the discovery and development phase, where the survival of the company depends on successful progression of assets like LP-300 and LP-184 through clinical trials. The overall growth and income profile is characterized by zero current income generation and zero reported revenue growth, relying entirely on the potential future value of its clinical pipeline to drive future financial performance and shareholder equity appreciation.